EIA seroconversion in 11/17 (65%) patients (IgG>IgA>IgM) and SRA seroconversion in 8/17 (47%), whereas none of 3 medical patients re-exposed to heparin developed seroconversion. Anti-PF4/heparin IgG became detectable at day 7 (median), i.e., no sooner than observed in typical-onset HIT. The high proportion of SRA-positivity among EIA-seroconverting patients (8/11 [73%]) suggests that patients with previous HIT may be especially predisposed to forming recurrent antibodies with platelet-activating properties. We conclude that among patients with a previous history of HIT who are re-
exposed to intraoperative (but not postoperative) heparin the risk of recurrent HIT appears to be low, but is possible if antibodies with strong heparin-independent plateletactivating properties are formed.
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Introduction
Heparin-induced thrombocytopenia (HIT) is an immune-mediated prothrombotic adverse drug reaction with a frequency of at least 1% in certain clinical circumstances, such as during unfractionated heparin (UFH) thromboprophylaxis following orthopedic or cardiac surgery. 1, 2 HIT represents a rather unusual immune response, 3, 4 including the relatively rapid formation of anti-platelet factor 4 (PF4)/heparin antibodies even upon a first heparin exposure (median time to detectability of IgG class antibodies, 4-5 days 5, 6 ) and the transient appearance 4 of platelet-activating IgG class antibodies that recognize multimolecular complexes of PF4 bound to heparin. 7, 8 It remains uncertain what the risk of recurrent HIT is in patients with a previous history of HIT who receive a subsequent re-exposure to heparin: to our knowledge, there are only two published cases of patients who had two well-documented distinct episodes of HIT. 9,10 Poetzsch and coworkers 11 reported on 10 patients with a previous history of HIT who received a repeat course of UFH for cardiac surgery; surprisingly, none of the 10 patients formed anti-PF4/heparin antibodies, suggesting that the probability of forming repeat antibodies might even be lower than expected, given that approximately 50% of patients form at least a weak anti-PF4/heparin immune response after cardiac surgery, 2, 12 and approximately 12% (median of 5 studies [range, 3% to 20% 2,12-15 ])
develop a positive platelet activation assay. Two additional studies in hemodialysis patients found no recurrent antibodies or recurrent HIT among 8 patients with previous hemodialysis-associated HIT who-following disappearance of HIT antibodiesresumed anticoagulation either with UFH 16 or with low-molecular-weight heparin (LMWH) 17 for their long-term hemodialysis.
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In a typical T cell-dependent immune response, a recall rate of nearly 100% should be expected, whereas a frequency of antibody production similar to that observed in prospective studies on HIT should be expected if the immune response in patients with previous HIT is similar to that of the general population undergoing heparin exposure with the same type of surgery. Moreover, specific questions that address features of HIT immunobiology can be addressed: does anti-PF4/heparin antibody formation occur more rapidly with re-exposure versus a first episode of HIT? does the distribution of immunoglobulin isotypes, or the proportion of anti-PF4/heparin antibodies with plateletactivating antibodies, differ from that observed in other patient populations that form anti-PF4/heparin antibodies?
In our study, we examined the serological profile of patients who underwent a repeat heparin exposure following an episode of well-documented previous HIT. Our primary aim was to study serial post-exposure serum samples to determine what the frequency of repeat antibody formation is, its antibody isotype profile, and its timing. We also determined whether any of our heparin re-exposed patients developed recurrent HIT, and if so, to characterize the serological features of a recurrent HIT immune response.
Methods and Patients

Patients
Clinical and laboratory files were reviewed to identify patients with well-documented previous HIT who underwent re-exposure to heparin. In most cases, the re-exposure had been planned, based upon a strong indication for UFH such as intraoperative inhibition by high concentrations of heparin (100 U/mL, final) as evidence for heparindependence of reactivity in the EIA.
Timing of Repeat Seroconversion in Relation to Previous Timing of Onset of HIT
We used the first day of platelet count fall (day of starting heparin = day 0) to determine the presumed date of seroconversion for the episode of previous HIT. This is a conservative estimate of seroconversion, since it is known that antibodies usually become detectable a median of 2 days prior to the beginning of the HIT-related platelet count decline. 6 For judging the day of seroconversion following heparin re-exposure, we used the earliest seroconversion date, if antibodies of more than one isotype were formed.
Recurrent HIT
For judging whether a patient developed recurrent HIT, we examined serial platelet counts in relation to seroconversion, judged by both the SRA and isotype-specific anti-PF4/heparin EIAs, testing all available serial post-exposure blood samples in relation to the baseline (i.e., the sample obtained shortly before heparin re-exposure). To classify a patient as having recurrent HIT, both a positive EIA-IgG and platelet-activating antibodies (by SRA) were required that were detectable at the time of a new platelet count fall (minimum, 30%) that was otherwise unexplained by the clinical circumstances; as a general rule, a platelet count fall that occurred in relation to cardiac surgery, and prior to development of a positive SRA, was regarded as not being HIT-related. Among the SRA-seroconverting patients, we also evaluated the magnitude of serum-induced platelet activation that occurred at 0 IU/mL UFH (i.e., percent serotonin-release at buffer control), since thrombocytopenia due to HIT antibodies would not be expected to occur in the absence of continuing heparin exposure, unless the patient had antibodies that caused substantial platelet activation in the absence of heparin (i.e., HIT antibodies with so-called heparin-independent platelet-activating properties). 21 If thrombocytopenia occurred in an SRA-seroconverting patient who received postoperative fondaparinux thromboprophylaxis, we tested for in-vitro fondaparinux cross-reactivity.
Results
We identified 20 patients with previous HIT (definite, n=16; probable, n=4) who underwent repeat re-exposure to heparin (UFH, n=19; LMWH, n=1), occurring 4.4 years (mean [range, 8 weeks to 13.5 years]) post-HIT diagnosis. We had available 10 samples (median) per patient (last blood sample, median 11 days after re-exposure). is that they help to explain how a patient could develop recurrent HIT one week postcardiac surgery even when no postoperative heparin was being given, i.e., the antibodies are able to activate platelets strongly in the absence of pharmacological heparin. EIA seroconversion between surgical and medical patient groups).
Frequency of Seroconversion with Repeat Heparin Exposure
Of these 11 immune responses, 9 represented IgG anti-PF4/heparin seroconversions that were classified as strong (+++) based upon a peak OD reading ≥ 2.00 OD units; 8 of these 9 patients with strong EIA-IgG seroconversion also developed a positive SRA. The most common antibody isotype was IgG (n=9 patients), followed by IgA (n=7) and IgM (n=6; again, patient 18 is only counted once).
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We observed one patient (patient 11) who developed seroconversion to a strongpositive SRA (which was inhibited by high heparin) but in whom neither the preoperative sample (weakly positive EIA-IgG measuring 0.55 OD units) nor the postoperative sample with the highest EIA reactivity (2.14 OD units) exhibited >30% inhibition by high heparin. This finding corroborates previous observations 23, 24 that on some occasions platelet-activating antibodies can be present even when the high heparin maneuver fails to inhibit reactivity in the EIA.
For seven patients, we were able to compare the anti-PF4/heparin antibody isotype profile for the patient's previous episode of HIT with the isotype profile associated with anti-PF4/heparin antibody seroconversion following heparin re-exposure. Figure 3C shows the serial EIA and SRA results for the approximate 140-day period following the episode of HIT that preceded subsequent UFH
re-exposure at cardiac surgery, indicating that the EIA-IgG remained moderately positive (OD = 1.98 units) on the day prior to heparin re-exposure at surgery). Figure 3D shows that following UFH re-exposure at cardiac surgery, both the IgG and IgA levels, which declined modestly in the early postoperative period (presumably related to hemodilution) then showed subsequent increases consistent with seroconversion. However, despite the post-reexposure IgG levels rising to as well as delayed recovery of thrombocytopenia after stopping heparin, 32 and which plausibly explains why this patient developed HIT one week post-cardiac surgery, even though no postoperative heparin was being given. A practical consequence of this clinical observation is that patients with previous HIT who undergo heparin rechallenge should undergo platelet count monitoring, perhaps for as long as 10 days, even if they do not receive any postoperative heparin.
Our study also provides a systematic assessment of the timing of repeat anti-PF4/heparin antibody responses in a patient population with well-characterized previous HIT. We found that antibody formation did not occur any more quickly upon heparin reexposure than had occurred with their previous HIT episode (when this information was available), or in relation to the known timing of typical-onset HIT, which is
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From approximately day 6 to 7 (median). 4 This median time to detectability of newly-forming anti-PF4/heparin antibodies of approximately one week-irrespective of whether previous exposure to heparin has occurred or not, 5 or even whether a patient has had a previous history of HIT (present report)-provides support to the recent concept that HIT represents a misdirected immune response, 33 in which all cases of HIT-even when patients are exposed to heparin for the first time-likely represent a type of "secondary" immune response, perhaps as a result of preceding "primary" immunization that may have occurred as a result of exposure to PF4-coated bacteria. 33 Interestingly, in most instances, the isotype profile of the subsequent rechallenge-induced seroconversion response resembled that seen at the time of the previous episode of HIT (Figure 2 ), suggesting that the HIT immune response is indeed a secondary (anamnestic) response involving long-lived B-lymphocytes rather than a de-novo immune reaction; the latter would likely result in a more heterogeneous pattern of isotype response.
We also observed that for 9 of our 17 surgical patients, anti-PF4/heparin IgG antibodies were present at the time of rechallenge, although none had platelet-activating antibodies (i.e., all nine patients had a negative SRA at the time of rechallenge). Nevertheless, our data suggest that deliberate intraoperative UFH re-exposure for patients who require cardiac or vascular surgery is a reasonable treatment option, provided that platelet-activating antibodies are not detectable prior to surgery, especially given that most medical centers will not have experience with non-heparin anticoagulants for cardiac or vascular surgery.
For For antibodies generated following heparin re-exposure. For each of 5 (3, 8, 15, 16, 20) , the isotype profiles were identical for the previous HIT episode and the antibodies generated following UFH rechallenge, whereas for the two remaining patients (10, 11), one of the 
